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592Deep vein thrombosis in noncritically ill patients with coronavirus
disease 2019 pneumonia: deep vein thrombosis in nonintensive
care unit patients
Xavier Jimenez-Guiu, MD,a Malka Huici-Sánchez, MD,a Antonio Rmera-Villegas, MD, PhD,a
Alexandre Izquierdo-Miranda, MD,b Ana Sancho-Cerro, MD,c and Ramon Vila-Coll, MD, FEBVS,a
Hospitalet del Llobregat, SpainABSTRACT
Background: Venous thromboembolic events have been one of the main causes of mortality among hospitalized pa-
tients with coronavirus disease 2019 (COVID-19) pneumonia. The aim of our study was to describe the prevalence of deep
vein thrombosis (DVT) in noncritically ill patients with COVID-19 pneumonia and correlate such observations with the
thromboprophylaxis received.
Methods:We performed a prospective cohort study of 67 patients admitted to the hospital for COVID-19 pneumonia. The
diagnosis was confirmed using polymerase chain reaction testing of nasopharyngeal specimens. The deep veins were
examined using compression duplex ultrasonography with the transducer on B-mode. The patients were separated into
two groups for statistical analysis: those receiving low-molecular-weight heparin prophylaxis and those receiving inter-
mediate or complete anticoagulation treatment. Risk analysis and logistic regression were performed.
Results:Of the 67 patients, 57 were included in the present study after applying the inclusion and exclusion criteria; 49.1%
were women, and the patient mean age was 71.3 years. All 57 patients had undergone compression duplex ultraso-
nography. Of these 57 patients, 6 were diagnosed with DVT, for an in-hospital rate of DVT in patients with COVID-19
pneumonia of 10.5%. All the patients who had presented with DVT had been receiving low-molecular-weight heparin
prophylaxis. The patients receiving prophylactic anticoagulation treatment had a greater risk of DVT (16.21%; 95% con-
fidence interval, 0.04-0.28; P¼ .056) compared with those receiving intermediate or complete anticoagulation treatment.
We also found a protective factor for DVT in the intermediate or complete anticoagulation treatment group (odds ratio,
0.19; 95% confidence interval, 0.08-0.46; P < .05).
Conclusions: Noncritically ill, hospitalized patients with COVID-19 pneumonia have a high risk of DVT despite receipt of
correct, standard thromboprophylaxis. (J Vasc Surg Venous Lymphat Disord 2021;9:592-6.)
Keywords: COVID-19 pneumonia; Deep vein thrombosis; ThromboprophylaxisAfter the outbreak of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), healthcare systems around
the world have unified resources and knowledge to
contain the spread of the virus. Although coronaviruses
have been well studied, SARS-CoV-2 has been reported
to have particular characteristics that distinguish it
from other viruses of the same family. Compared with se-
vere acute respiratory syndrome coronavirus, SARS-CoV-
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doi.org/10.1016/j.jvsv.2020.08.028infect human hosts appears to be greater and the incu-
bation period longer.1 During infection, the plasma levels
of proinflammatory and prothrombotic cytokines such
as C-reactive protein, interleukin (IL)-6, IL-8, and D-dimer
might have a role in the physiopathology of coronavirus
disease 2019 (COVID-19)einduced SARS. Some studies
have reported high levels of those cytokines, especially
in patients with a more serious condition.2
One main complication reported to develop in hospi-
talized patients with COVID-19 has been venous throm-
boembolic events. In general, venous thromboembolic
events are one of the main causes of mortality among
hospitalized patients.2 Diagnostic algorithms rely on clin-
ical history, physical examination findings, and previous
diseases to assess clinical probability scales. Compression
duplex ultrasonography (CDUS) and computed tomog-
raphy angiography are the reference standard diagnostic
tools for evaluating deep vein thrombosis (DVT) and pul-
monary embolism (PE).3,4 Because 20% of patients
admitted to intensive care units (ICUs) will experience a
thromboembolic event,5 numerous diagnostic
ARTICLE HIGHLIGHTS
d Type of Research: Single-center, prospective, non-
randomized cohort study
d Key Findings: Patients with coronavirus disease 2019
pneumonia treated with prophylactic, intermediate,
or complete anticoagulation doses of low-
molecular-weight heparin had a prevalence of lower
extremity deep vein thrombosis (DVT) of 10.5%, with
a cumulative incidence of 16.2% for those receiving a
prophylactic dosage. We found a protective factor
against DVT for patients receiving intermediate or
complete anticoagulation treatment.
d Take Home Message: Noncritically ill patients with
coronavirus disease 2019 pneumonia have a high
risk of lower limb DVT despite correct prophylactic
treatment.
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albeit without any worldwide consensus reached.6-8
The incidence of PE has been reported for critically ill
patients with COVID-19 pneumonia5 and in a retrospec-
tive analysis by Chen et al.9 In the latter study, the inves-
tigators reported that 25 of 1008 patients with COVID-19
had presented with PE.9 Similarly, few data regarding the
prevalence of DVT in hospitalized patients in noncritical
care conditions with COVID-19 have been reported.
Only 2 studies have recently reported an incidence of
asymptomatic infrapopliteal DVT of 5.6% to 14.1% in pa-
tients in common wards.10,11
Therefore, we have described the prevalence of DVT
among noncritically ill, hospitalized patients with
COVID-19 pneumonia and correlated the findings with
the thromboprophylaxis the patients received.
METHODS
We performed a prospective cohort study of 67 patients
who had been admitted to our hospital because of
COVID-19 pneumonia during April 2020. The diagnosis
of COVID-19 was confirmed using polymerase chain reac-
tion testing of nasopharyngeal specimens.
All the patients were assessed clinically by a vascular
surgeon, and the Wells score was calculated. The inclu-
sion criteria were as follows: the presence of COVID-19
pneumonia, presentation to the emergency department,
and hospitalization required. The exclusion criteria were
as follows: (1) palliative treatment, (2) pregnancy, (3) diag-
nosis of a thromboembolic event before hospital admis-
sion, (4) ICU treatment required, and (5) patient refusal to
participate in the present study.
The demographic data recorded included cardiovascu-
lar risk factors (eg, dyslipidemia, hypertension, diabetes
mellitus, smoking), chronic pulmonary or cardiac dis-
eases (eg, chronic pulmonary obstructive disease,
chronic ischemia heart disease, atrial fibrillation), the
need for oxygen therapy, and the need for corticosteroid
therapy (1 mg/kg of intravenous methylprednisolone
administered every 24 hours). We also analyze the pres-
ence of sepsis using the diagnostic criteria of the
Sepsis-3 International Consensus.12 We used the Barthel
Index as an observer-based instrument to measure the
patients’ physical function.13
Regardless of the symptoms and Wells score, all the pa-
tients had undergone bilateral CDUS, including the
femoral, popliteal, calf, peroneal and tibial veins. Lower
limb venous CDUS was performed using a Philips Epiq
5 scanner (Phillips HealthCare NV, Amsterdam, The
Netherlands). A 5- to 10-MHz transducer was used for
the infrainguinal area and a 3.5-MHz transducer was
used for the abdominal vessels. The deep veins were
examined using compression with the transducer on B-
mode at 2-cm intervals.
Color Doppler flow was used to detect luminal filling
defects, and Doppler tracings were obtained to detectspontaneous flow and phasicity. The diagnosis was
established using the following ultrasound criteria: (1)
no collapse or partial collapse of the vein lumen with
transducer compression; (2) thrombus visualization
within the vein lumen; (3) the absence of spontaneous
venous flow; (4) the absence of a Doppler signal; and (5)
an increase in vein diameter. At least two of these criteria
were required for DVT to be diagnosed. We performed
extended CDUS (including the infrapopliteal veins).
Limited protocols required that a second study was per-
formed within 5 to 7 days to safely exclude DVT.14
We collected the laboratory tests to obtain the D-dimer
and IL-6 values. The D-dimer levels were obtained using
the ACL TOP-500 (Instrumentation Laboratory, Bedford,
Mass), with D-dimer high sensitivity as the reagent. A pos-
itive D-dimer level was set at 250 mg/L D-dimer units. The
IL-6 levels were analyzed using a Cobas 8000 modular
analyzer (Roche Diagnostics International AG, Risch-
Rotkreuz, Switzerland).
DVTprophylaxiswas assessed according toour hospital’s
protocol. Patients requiring anticoagulation therapy
received low-molecular-weight heparin (LMWH) at
different dosages. Those with an underlying disease (eg,
atrial fibrillation; a prosthetic heart valve) had received
LMWH at the complete anticoagulation dosage (1.5 mg/
kg of enoxaparin every 24 hours). Those at high risk (eg,
body mass index >30 kg/m2, thrombophilia, a history of
thromboembolic disease, active cancer) had received
LMWH at an intermediate dosage (0.5 mg/kg of enoxa-
parin every 12 hours). The remaining patients had received
LMWH at a prophylactic dosage (40 mg of enoxaparin
every 24 hours). Bleeding complications were recorded
and categorized according to a consensus report from
the Bleeding Academic Research Consortium.15
Categorical variables are presented as frequencies and
percentages. Normally distributed continuous variables












Diabetes mellitus 18 (31.6)
Smoking 9 (15.8)
COPD 8 (14)




FiO2, 21% 19 (33.3)
NC 20 (35.1)
SFM (FiO2, 26%) 3 (5.3)
SFM (FiO2, 35%) 9 (15.8)




COPD, Chronic obstructive pulmonary disease; FiO2, fraction of inspired
oxygen; NC, nasal cannula; SFM, simple face mask.
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sented as the median and interquartile range.
The patients were divided into two groups for statistical
analysis: those who had received LMWH prophylaxis and
those who had received intermediate or complete anti-
coagulation treatment. We performed a risk analysis
and logistic regression test. Differences between the
two groups were assessed using the c2 test (Yates correc-
tion) and the Student t test, as appropriate. Statistical sig-
nificance was considered present for P values <.05.
The investigation ethics committee of Bellvitge Univer-
sity Hospital approved the present study (reference no.
PR153/20). The study was performed in accordance
with the 2013 Declaration of Helsinki consensus. All pa-
tient data were treated in accordance with the General
Data Protection Regulations and Spanish Organic Law
15/1999 of December 13 on Protection of Personal Data
and Royal Decree 1720/2007. All data were codified using
a numeric code anonymously established for the pur-
poses of the present study. All the patients were properly
informed and provided written informed consent. The
investigation data were saved in an electronic directory
with restricted access supervised by the information sys-
tem department of Bellvitge University Hospital. Statisti-
cal analyses were performed using R, version 3.4.0,
software (R Foundation for Statistical Computing,
Vienna, Austria).
RESULTS
Our study population included 67 patients admitted to
the hospital with unilateral or bilateral pneumonia
caused by COVID-19 during April 2020. Of the 67 pa-
tients, 10 were excluded from the present study in accor-
dance with the inclusion and exclusion criteria. Of the 10
patients, 3 had refused to participate, 3 had received
palliative treatment, and 4 had had a diagnosis of a
thromboembolic event before hospital admission (3
had presented with DVT and PE and 1 with popliteal
DVT). Thus, 57 patients were finally included, including
28 women (49.1%) and 29 men (50.9%). The mean age
of the 57 patients was 71.3 6 12.7 years. All included pa-
tients had undergone CDUS within a median of 9 days
of hospitalization (interquartile range, 6-15 days).
The baseline characteristics of our sample are presented
in Table.
The clinical pretest probability of venous thromboembo-
lism determined using the Wells score was unlikely for
98.2% of the patients and likely for 1.8% of patients. Of
the57patients, 6werediagnosedwithDVT. Thus, theprev-
alence of in-hospital DVT in the patients with COVID-19
pneumonia was 10.5%. Of the six patients with DVT, five
had had an unlikely Wells score and one had had a likely
Wells score. All the patients had received LMWH treat-
ment. However, different dosages hadbeen administered
in accordance with the hospital protocol: 64.9% had
received a prophylactic dosage; 21.1%, intermediateanticoagulation treatment; and 14%, complete anticoagu-
lation treatment because of an underlying disease.
All six of our patients had experienced asymptomatic
DVT, except for one patient who had mentioned pain
in the calf region and had had a swollen leg in the previ-
ous 24 hours. The most common area affected was distal
(83.3%), and one patient had presented with femoropo-
pliteal DVT (16.7%). All venous thromboembolic events
had occurred in patients receiving a prophylactic dosage
of LMWH. No such events were observed in the patients
receiving intermediate or complete anticoagulation dos-
ages. Only one patient with DVT had presented with
worsening of respiratory symptoms and no thromboem-
bolism. That patient had required ICU care. The remain-
ing patients did not experience worsening of symptoms
from COVID-19 infection.
All patients diagnosed with DVT were treated with
LMWH at anticoagulation dosages during hospitaliza-
tion. The patients were then switched to oral anticoagu-
lation treatment during ambulatory follow-up for
$3 months.
When analyzing the risk, we found a risk difference of
16.21% (95% confidence interval, 0.04%-0.28%) for pa-
tients receiving LMWH prophylaxis vs intermediate or
complete anticoagulation treatment. However, the
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Volume 9, Number 3difference was not statistically significant (P ¼ .056). Lo-
gistic regression was performed, which revealed an
odds ratio of 0.19 (95% confidence interval, 0.08-0.46;
P < .05) for the intermediate or complete anticoagula-
tion treatment group.
Corticosteroid treatment was used for 25 patients
(43%). The incidence of DVT was 12% for the patients
receiving corticosteroid treatment and 9.3% for the pa-
tients not receiving corticosteroid treatment. No statisti-
cally significant difference was found between the two
groups (P ¼ .74). Sepsis developed in 19 patients (33%).
We found a tendency for more cases of DVT in the pa-
tients with sepsis (21%) compared with the patients
without sepsis (5.2%; P ¼ .067).
We found that the mean D-dimer levels were 467 6
189 ng/mL in the patients without DVT and 576 6
570 ng/mL in the patients with DVT (P ¼ .64). Patients
with DVT had had a mean IL-6 level of 12.8 6 11.8 pg/
mL. The patients without DVT had had a mean IL-6 level
of 15.2 6 13.9 pg/mL (P ¼ .69).
Bleeding complications had developed in 1 patient in
the intermediate or complete anticoagulation group
(5%). No differences were observed between the two
groups (P ¼ .22).DISCUSSION
We found that noncritically ill patients with COVID-19
pneumonia have a high risk of DVT during hospital admis-
sion despite receiving standard-dose thromboprophy-
laxis. Venous thromboembolic disease has been
reported as one of the major complications occurring in
patientswithCOVID-19.9 Data reported from the initial au-
topsies shows that nonsuspected PE or DVT could ac-
count for 58% of deaths and for 33% was the main cause
of death.16 Nonetheless, it is not clearly known whether
venous thromboembolic events were the main cause of
clinicalworseninganddeathamonghospitalizedpatients
or had been complications induced by the severe pneu-
monia and inflammatory responses. Therefore, we believe
our efforts should also focus on the noncritically ill, hospi-
talized population to prevent the thromboembolic com-
plications, which have been the most common events.
To the best of our knowledge, our study is one of the
first to analyze asymptomatic DVT in a non-ICU setting.
Even with correct, standard prophylaxis with LMWH, a
DVT prevalence of 10.5% was observed in our study.
Although one of our patients had developed femoropo-
pliteal DVT, the remaining five patients had had infrapo-
pliteal DVT. Management of infrapopliteal DVT remains
under discussion; however, previously reported data of
a standard population demonstrated a proximal pro-
gression rate of 15.5%.17 We believe that infrapopliteal
DVT should be treated, because a procoagulant state ex-
ists in patients with COVID-19 that has not been studied
and could lead to higher progression rates.The high proportion of patients with DVT can be
explained by dysregulation of the coagulation system,
which has been observed in patients with COVID-19
pneumonia. A recent study by Panigada et al18 investi-
gated the inflammatory response occurring secondary
to COVID-19 by measuring blood from ICU-admitted pa-
tients using thromboelastography. Their findings high-
lighted that, more than the occurrence of an acute
disseminated intravascular coagulation (with a low
platelet count, low fibrinogen clotting activity, and high
fibrin degradation products), the inflammatory response
leads to a hypercoagulable state with high levels of
fibrinogen, D-dimer, C-reactive protein, VIII factor, von
Willebrand factor, low levels of antithrombin, and normal
platelet counts, prothrombin time, and activated partial
thromboplastin time.18 A high procoagulant state, in
addition to sepsis and medical treatment (eg, corticoste-
roid therapy) might be the reason patients with COVID-
19 pneumonia have a greater risk of thromboembolic
events compared with a standard hospitalized
population.
Anticoagulation protocols have been reported by many
societies, such as the International Society on Throm-
bosis and Hemostasis, North American Thrombosis
Forum, European Society of Vascular Medicine, and Inter-
national Union of Angiology, in which the standard pro-
phylaxis dosage has been recommended as LMWH
once daily.6
Also, our team observed a clear tendency toward a
greater cumulative incidence of 16.2% for patients
treated with LMWH at the prophylactic dosage
compared with the incidence for those patients
receiving intermediate or complete anticoagulation dos-
ages. Additionally, the logistic regression model demon-
strated that a protective factor against DVT was the use
of intermediate or complete anticoagulation treatment.
In addition, a recent study by Paranjpe et al19 found
that in a cohort of 2773 hospitalized patients with
COVID-19, in-hospital survival was greater for the patients
receiving anticoagulation therapy compared with the
survival of those who had not received such therapy.
Similarly, our results support those reported by Middel-
dorp et al10 and Demelo-Rodriguez et al,11 demonstrating
a high incidence of DVT in noncritically ill patients with
COVID-19.
The results from an autopsy study suggested that the
inflammatory response might have caused in situ immu-
nothrombosis in the microcirculation of the lungs.20 A
separate study reported by van Dam et al21 concluded
that the phenotype of pulmonary embolism in patients
with COVID-19 might differ from that for patients without
COVID-19 pneumonia. The investigators suggested that
in situ immunothrombosis was the main cause. Howev-
er, despite the sample size, the main limitation of their
study was that the patients had not undergone lower
limb CDUS.21
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findings notwithstanding, selected patients could
benefit from intermediate anticoagulation dosages and
avoid experiencing a thromboembolic event because
six of our patients, despite receiving standard prophy-
laxis, had developed DVT. These findings and results are
noteworthy, because they lead to the question of
whether standard prophylaxis treatments will be suffi-
cient and whether treatment to prevent DVT should be
more aggressive in patients with COVID-19 pneumonia.
Clinically randomized trials are required to best address
these questions to improve clinical practice and provide
better patient care.
The present study had only two main limitations. First,
because the sample size was small, the potential for sta-
tistically significant results was low. Second, the specific
COVID-19 treatments changed weekly owing to the rapid
advances occurring concerning COVID-19 during the
pandemic. Thus, external validity could have been
affected.
CONCLUSIONS
Noncritically ill patients admitted to the hospital
because of COVID-19 pneumonia have a high risk of
DVT despite receipt of correct, standard
thromboprophylaxis.
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